Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Change in Beneficial Ownership
SEC Form 4 Filing
Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports a transfer of 16,850 shares from the KBT Trust to direct ownership on April 2, 2025.
Summary
- On April 2, 2025, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, reported a change in his beneficial ownership of the company's common stock.
- 16,850 shares of common stock were transferred from the KBT Trust to Mr. Khattar's direct ownership.
- This transfer did not involve any consideration.
- Following the transaction, Mr. Khattar directly owns 1,008,683 shares of Supernus Pharmaceuticals.
- The KBT Trust now holds 1,005,600 shares.
Sentiment
Score: 5
Explanation: This is a neutral event, simply a reporting of a change in stock ownership. It doesn't inherently suggest positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market. It does not necessarily indicate a change in the company's performance or outlook.
Stakeholder Impact
- The change in ownership may have a minor impact on shareholder perception, but is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 04/02/2025 | Date of stock transfer from KBT Trust to Jack A. Khattar. |
| 04/03/2025 | Date of signature on the Form 4 filing. |
Keywords
beneficial ownership, Supernus Pharmaceuticals, Khattar, stock transfer, Form 4, SUPN, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.